HopeStage
Back to all studies
CompletedNCT03315897

Erythropoietin or Saline and Cognition in Bipolarity or Recurrent Depression

About this titleRead the official source — NCT03315897
Medication studyAges 18–65Denmark
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
CopenhagenSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 5, 2017
Recruitment status
Completed
Enrollment listed in the registry
103
Sponsor
Lars Vedel Kessing
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Denmark
Age range
From 18 Years to 65 Years
Official registry ID
NCT03315897
Official title
Show the full official title

Effects of Erythropoietin on Cognitive Functions and Neural Activity in Cognitively Impaired Remitted Patients With Bipolar Disorder or Recurrent Depressive Disorder and Healthy People: Study Protocol for a Randomized, Controlled Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Copenhagen

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Lars Vedel Kessing.

Did this study involve medication?

Yes. The study involved medication, including Erythropoietin and Saline.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies